Related Experiment Video
Updated: Dec 9, 2025
08:25
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.8K
Surface-enhanced Raman scattering sensing platform for detecting amyloid-β peptide interaction with an aggregation
Applied Optics
|September 9, 2020
Summary
Researchers developed a label-free SERS method to detect interactions between amyloid-beta peptides and an aggregation inhibitor. This technique can rapidly screen for new Alzheimer's disease (AD) therapeutics targeting amyloid-beta.
Area of Science:
- Biochemistry
- Neuroscience
- Analytical Chemistry
Background:
- Soluble amyloid-beta oligomers (AβO) are key contributors to Alzheimer's disease (AD) pathology.
- Current AD treatments manage symptoms but do not alter disease progression by targeting amyloid-beta (Aβ).
Purpose of the Study:
- To develop a label-free method for screening novel anti-AD therapeutic agents.
- To detect molecular interactions between Aβ peptides and the aggregation inhibitor spin-labeled fluorine (SLF).
Main Methods:
- Utilized a surface-enhanced Raman scattering (SERS) active substrate.
- Monitored molecular interactions by analyzing changes in spectral peak positions and intensity ratios near 1600 cm⁻¹ and 2900 cm⁻¹.
Main Results:
- Demonstrated the capability of SERS to detect interactions between Aβ peptides and SLF.
- Observed distinct changes in SERS spectral features indicative of molecular binding.
Conclusions:
- SERS spectroscopy shows significant potential for the rapid screening and identification of new anti-Aβ therapeutic agents.
- This label-free approach offers a promising avenue for developing disease-modifying therapies for Alzheimer's disease.
